Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01752933 · ClinicalTrials.gov registry record · Phase 2
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01752933 is a Phase 2 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT01752933, a Phase 2 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
A Phase 2 open-label, single-arm, non-randomized study in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with sorafenib using a Simon's 2-stage design. A set minimum number of patients must demonstrate disease control at 16 weeks to proceed to Stage 2. At Stage 2, a set number of patients must have disease control at 16 weeks to declare that SGI-110 is of interest in the treatment of advanced HCC after failure of prior sorafenib.
Interventions
- DRUG SGI-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01752933
The ClinicalTrials.gov registry entry for NCT01752933 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGI-110 is the first listed.
NCT01752933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01752933 about?
NCT01752933 is a clinical study titled "SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)". A Phase 2 open-label, single-arm, non-randomized study in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with sorafenib using a Simon's 2-stage design. A set minimum number of patients must demonstrate disease control at 16 weeks to proceed to Stage 2. A...
What is the current status of trial NCT01752933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2012-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01752933?
The interventions under investigation include: SGI-110 (DRUG).
Who is sponsoring clinical trial NCT01752933?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.